Tourmaline Bio (TRML) Earnings Date & Reports

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

TRML is expected to report earnings to fall 45.95% to -20 cents per share on August 10

Tourmaline Bio TRML Stock Earnings Reports

Q2'23

Est.

$-0.20

Q1'23

Beat

by $0.09

Q4'22

Missed

by $4.71

Q3'22

Missed

by $4.15

Q2'22

Missed

by $3.95

The last earnings report on May 11 showed earnings per share of -37 cents, beating the estimate of -45 cents. With 595.51K shares outstanding, the current market capitalization sits at 444.86M.

View a ticker or compare two or three

Compare

TRML